Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
DOI: 10.1080/2162402X.2019.1593802
Antonia Marazioti,
Georgia A Giotopoulou,
Georgios T. Stathopoulos,
Giannoula Ntaliarda,
Ioanna Giopanou,
Ioannis Lilis,
Magda Spella,
Maria Oplopoiou,
Sebastian Marwitz,
Torsten Goldmann,
Vasiliki Bravou,
Vassilios Papaleonidopoulos
Keywords: Carboxypeptidase 3/mutation/IL, 1β/lung cancer/urethane
Abstract:
Full-Text
